- Home
- VERU vs ASRT Comparison
VERU vs ASRT Comparison
Compare VERU & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- ASRT
- Stock Information
- Founded
- VERU 1971
- ASRT 1995
- Country
- VERU United States
- ASRT United States
- Employees
- VERU N/A
- ASRT N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- ASRT Health Care
- Exchange
- VERU Nasdaq
- ASRT Nasdaq
- Market Cap
- VERU 107.2M
- ASRT 105.8M
- IPO Year
- VERU 1990
- ASRT 1997
- Fundamental
- Price
- VERU $0.58
- ASRT $0.81
- Analyst Decision
- VERU Strong Buy
- ASRT Strong Buy
- Analyst Count
- VERU 4
- ASRT 4
- Target Price
- VERU $4.00
- ASRT $3.19
- AVG Volume (30 Days)
- VERU 996.7K
- ASRT 862.2K
- Earning Date
- VERU 12-06-2024
- ASRT 11-11-2024
- Dividend Yield
- VERU N/A
- ASRT N/A
- EPS Growth
- VERU N/A
- ASRT N/A
- EPS
- VERU N/A
- ASRT N/A
- Revenue
- VERU $14,091,909.00
- ASRT $125,763,000.00
- Revenue This Year
- VERU N/A
- ASRT N/A
- Revenue Next Year
- VERU N/A
- ASRT $4.68
- P/E Ratio
- VERU N/A
- ASRT N/A
- Revenue Growth
- VERU N/A
- ASRT N/A
- 52 Week Low
- VERU $0.36
- ASRT $0.73
- 52 Week High
- VERU $1.92
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- VERU 24.06
- ASRT 30.77
- Support Level
- VERU $0.72
- ASRT $0.82
- Resistance Level
- VERU $0.83
- ASRT $1.07
- Average True Range (ATR)
- VERU 0.06
- ASRT 0.07
- MACD
- VERU -0.02
- ASRT -0.02
- Stochastic Oscillator
- VERU 1.38
- ASRT 8.29
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.